Sains Malaysiana 44(7)(2015): 1061–1065

Interaction of Imipenem and Tigecycline against Carbapenem-Resistant Acinetobacter baumanii: The Relativity of Synergism

(Interaksi Imipenem dan Tigecycline terhadap Rintang-Carbapenem Acinetobacter baumanii: Kerelatifan Sinergisme)

H. ALFIZAH¹, O.Z. SITI SARAH² & M.Z. NORAZIAH²*

¹Dept. of Medical Microbiology & Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia

²School of Diagnostic and Applied Health Sciences, Faculty of Health Sciences

Universiti Kebangsaan Malaysia, Jalan Raja Muda Abd Aziz, 50300 Kuala Lumpur, Malaysia

Diserahkan: 26 Julai 2013/Diterima: 6 April 2015

ABSTRACT

Acinetobacter baumanii is an opportunistic bacterium that causes widespread nosocomial infections and tends to be multi-resistant to most of antibiotics. Tigecycline is a well-known antibiotic that possesses a wide-range of activities and is very active in vitro towards a variety of resistant pathogens, including A. baumanii. The aim of this study was to evaluate the effects of the imipenem and tigecycline combination against carbapenem-resistant A. baumanii (CRAB). The minimal inhibitory concentration (MIC) was determined using the E-test method. The microbroth checkerboard technique was employed to determine the effects of the imipenem and tigecycline interaction by obtaining the fractional inhibitory concentration (FIC) index value. A time kill (TK) study was performed to identify any synergistic effects when both imipenem and tigecycline were used against CRAB strains. The result demonstrated that all A. baumanni strains exhibited imipenem MIC values of 32 μg/mL. The combination of imipenem and tigecycline demonstrated an additive effect (FIC > 0.5-4) against all of the strains and synergistic activity (decrement of > 2 log10 CFU/mL) towards AC 34/07 and AC 32/06 strains. The use of imipenem in combination with tigecycline resulted in a more efficient activity and an increased capability to control CRAB infections. This effect showed potential combination and may be of importance in the development or modification of antimicrobial agents for the treatment of CRAB infections.

Keywords: Acinetobacter baumanii; carbapenem-resistant; imipenem; tigecycline

ABSTRAK

Acinetobacter baumanii adalah bakteria oportunis yang menyebabkan jangkitan nosokomial secara meluas dan cenderung untuk menjadi multirintang terhadap kebanyakan antibiotik. Tigecycline adalah antibiotik yang mempunyai pelbagai aktiviti dan sangat aktif secara in vitro terhadap pelbagai patogen rintang antibiotik, termasuklah A. baumanii. Tujuan kajian ini adalah untuk menilai kesan dan gabungan antibiotik imipenem dan tigecycline terhadap A. baumanii rintang-karbapenem (CRAB). Kepekatan perencatan minimum (MIC) ditentukan dengan menggunakan kaedah E-test. Teknik papan penyemak mikrokaldu digunakan untuk menentukan kesan imipenem dan interaksinya dengan tigecycline dengan mendapatkan nilai indeks kepekatan rencatan berperingkat (FIC). Ujian masa membunuh (TK) telah dijalankan untuk mengenal pasti kesan sinergi apabila kedua-dua imipenem dan tigecycline digunakan terhadap strain CRAB. Hasil ujian menunjukkan bahawa semua strain A. baumanni memberi nilai imipenem MIC sebanyak 32 μg/mL. Gabungan imipenem dan tigecycline menunjukkan kesan tambahan (FIC> 0,5-4) terhadap semua strain yang diuji dan aktiviti sinergi (pengurangan sebanyak> 2 log10 CFU/mL) terhadap strain AC 34/07 dan AC 32/06. Penggunaan kombinasi imipenem dan tigecycline menghasilkan aktiviti yang lebih cekap dan meningkatkan kemampuan untuk mengawal jangkitan CRAB. Kesan ini menunjukkan kombinasi yang berpotensi dan mungkin penting dalam pembangunan atau pengubahsuaian agen antimikrob untuk rawatan jangkitan CRAB.

Kata kunci: Acinetobacter baumani; imipenem I; rintang-karbapenem; tigecycline

RUJUKAN

Al-Dabaibah, N., Obeidat, N.M. & Shehabi, A.A. 2012. Epidemiology features of Acinetobacter baumannii colonizing respiratory tracts of ICU patients. The Intern. Arabic J. Antimicrob. Agents 2(2) doi: 10.3823/710.

Bonomo, R.A. & Szabo, D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43: S49-S56.

Bou, G., Cerveró, G., Dominguez, M.A., Quereda, C. & Beltraán, M. 2000. Characterization of nososcomial outbreak caused by a multiresistant Acinetobacter baumaii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumanii is not due solely to the presence of β-lactamases. J. Clin. Microbiol. 38: 3299-3305.

Carmeli, Y., Akova, M., Cornaglia, G., Daikos, G.L., Garau, J., Harbarth, S., Rossolini, G.M., Souli, M. & Giamarellou, H. 2010. Controlling the spread of carbapenemaseproducing Gram-negatives: Therapeutic approach and infection control. Clin. Microbiol. Infect. 16: 102-111.

Castanheira, M., Sader, H.S., Deshpande, L.M., Fritsche, T.R. & Jones, R.N. 2008. Antimicrobial activity of tigecycline and other broad spectrum antimicrobials tested against serine carbapenemase and metallo-β lactamase-producing Enterobacteriaceae: Report from the antimicrobial surveillance program. Antimicrob. Agents Chemother. 52: 570-573.

Chaaria, A., Mnifb, B., Bahloula, M., Mahjoubib, F., Chtaraa, K., Turkia, O., Gharbia, N., Chellya, H., Hammamib, A. & Bouaziz, M. 2013. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiology, clinical characteristics, and prognosis factors. Intern. J. Infect. Dis. 17: e1225-e1228.

Clinical and Laboratory Standard Institute (CLSI). 2011. Performance standards for antimicrobial susceptibility testing; twenty-first information supplement, M100-S21.

Domaracki, B.E., Evans, A.M. & Venezia, R.A. 2000. Vancomycin and oxacillin yynergy for methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 44: 1394-1396.

Eliopoulos, G.M. & Moellering, R.C. 1991. Laboratory methods used to assess the activity of antimicrobial combinations. In Antibiotics in Laboratory Medicine. 3rd ed., edited by Lorian, V. Baltimore, MD: Williams & Wilkins. pp. 432-492.

Fishbain, J. & Peleg, A.Y. 2010. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51: 79-84.

Fritsche, T.R., Strabala, P.A., Sader, H.S., Dowzicky, M.J. & Jones, R.N. 2005. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant islates. Diagn. Microbiol. Infect. Dis. 52: 209-213.

Garnacho-Montero, J. & Amaya-Villar, R. 2010. Multiresistant Acinetobacter baumannii infections: Epidemiology and management. Curr. Opin. Infect. Dis. 23: 332-339.

Henwood, C.J., Gatward, T., Warner, M., James, D., Stockdale, M.W., Spence, R.P., Towner, K.J., Livermore, D.M. & Woodford, N. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49: 479-487.

Karageorgopoulos, D.E., Kelesidis, T., Kelesidis, I. & Falagas, M.E. 2008. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence. J. Antimicrob. Chemother. 62: 45-55.

Kuo, L.C., Yu, C.J., Kuo, M.L., Chen, W.N., Chang, C.K. & Lin, H.I. 2008. Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: A horizontal surveillance study. Int. J. Antimicrob. Agents 31: 420-426.

Lee, N.Y., Wang, C.L., Chuang, Y.C., Yu, W.L., Lee, H.C. & Chang, C.M. 2007. Combination carbapenem-ampicillin-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: Four case reports and an in vitro combination synergy study. Pharmacotherapy 27: 1506-1511.

Lim, T.P., Tan, T.Y., Lee, W., Sasikala, S., Tan, T.T., Hsu, L.Y. & Kwa, A.L. 2011. In vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLOS 6: e18485.

Lolans, K., Rice, T.W., Munoz-Price, L.S. & Quinn, J.P. 2006. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother. 50: 2941-2945.

Navon-Venezia, S., Leavitt, A. & Carmeli, Y. 2007. High tigecyline resistance in multidrugresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59: 772-774.

Pachon-Ibanez, M.E., Jimenez-Mejias, M.E., Pichardo, C., Lianos, A.C. & Pachon, J. 2004. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48: 4479-4481.

Peleg, A.Y., Seifert, H. & Paterson, D. 2008. Acinetobacter baumanii: Emergence of successful pathogen. Clin. Microbiol. Rev. 21: 538-592.

Petersen, P.J., Labthavikul, P., Jones, C.H. & Bradford, P.A. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J. Antimicrob. Chemother. 57: 573-576.

Rahal, J.J., Urban, C. & Segal-Maurer, S. 2002. Nosocomial antibiotic resistance in multiple gram-negative species: Experience at one hospital with squeezing the resistance balloon at multiple sites. Clin. Infect. Dis. 34: 409-503.

Rand, K.H. & Houck, H. 2004. Synergy of daptomycin with oxacillin and other B-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48: 2871-2875.

Scheetz, M.H., Qi, C., Warren, J.R., Postelnick, M.J., Zembower, T., Obias, A. & Noskin, G.A. 2007. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or –resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626.

Tsakiridou, E., Makris, D., Daniil, Z., Manoulakas, E., Chatzipantazi, V., Vlachos, O., Xidopoulos, G., Charalampidou, O. & Zakynthinos, E. 2014. Acinetobacter baumannii infection in prior ICU bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. BioMed. Res. Intern. Article ID 193516.

Wareham, D.W. & Bean, D.C. 2006. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Annals Clin. Microbiol. Antimicrob. 5: 10.

Yoon, J., Urban, C., Terzian, C., Mariano, N. & Rahal, J.J. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48: 753-757.

*Pengarang untuk surat-menyurat; email: nora@medic.ukm.my